Matthew Weston
Stock Analyst at UBS
(2.79)
# 1,574
Out of 5,182 analysts
6
Total ratings
100%
Success rate
29.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Weston
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Downgrades: Neutral | n/a | $45.90 | - | 1 | Jan 16, 2026 | |
| DBX Dropbox | Assumes: Sell | $29 → $27 | $23.91 | +12.92% | 1 | Sep 18, 2025 | |
| NVO Novo Nordisk | Downgrades: Neutral | n/a | $41.20 | - | 1 | Aug 5, 2025 | |
| NVS Novartis AG | Downgrades: Neutral | n/a | $144.19 | - | 1 | Feb 13, 2025 | |
| AZN AstraZeneca | Upgrades: Buy | n/a | $187.51 | - | 2 | Feb 13, 2025 |
Sanofi
Jan 16, 2026
Downgrades: Neutral
Price Target: n/a
Current: $45.90
Upside: -
Dropbox
Sep 18, 2025
Assumes: Sell
Price Target: $29 → $27
Current: $23.91
Upside: +12.92%
Novo Nordisk
Aug 5, 2025
Downgrades: Neutral
Price Target: n/a
Current: $41.20
Upside: -
Novartis AG
Feb 13, 2025
Downgrades: Neutral
Price Target: n/a
Current: $144.19
Upside: -
AstraZeneca
Feb 13, 2025
Upgrades: Buy
Price Target: n/a
Current: $187.51
Upside: -